Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

ons.

"The decision to trigger data cutoff and analysis based on trial duration relies on our level of confidence that the assumptions in the sample size calculations are appropriate; the most significant of which is the behavior of the control group. The guidance from the independent DMB combined with simulations we have performed based on the long-term follow-up from our Phase 2 trial gives us confidence that the timing of this analysis will provide adequate patient follow-up needed to retain the pre-specified statistical power of the trial. It is important to note that the DMB assessment was performed in a manner which ensured blinding and the integrity of this pivotal Phase 3 trial."

Third Quarter 2007 Financial Review

Favrille also reported its financial results for the third quarter of 2007. For the three and nine months ended September 30, 2007, the Company reported net losses of $12.3 million, or $0.37 per share, and $35.2 million, or $1.10 per share, respectively, compared to a net loss of $9.6 million, or $0.33 per share, and $30.3 million, or $1.13 per share, for the same periods in 2006.

Research and development expense was approximately $9.5 million and $27.1 million for the three and nine months ended September 30, 2007, respectively, compared to approximately $7.5 million and $23.4 million for the same periods in 2006. The increases were primarily due to additional expenses for personnel and stock-based compensation and increases in validation, rent and operating costs, supplies and depreciation related to the commercial-scale manufacturing facility expansion; offset by decreases in expenses associated with the pivotal Phase 3 clinical trial, which completed patient enrollment in January 2006. Total stock-based compensation included in research and development was approximately $670,000 and $1.7 million for the three and nine months ended September 30, 2007, respectively, compared to approximately $458,000 and $1.4 million for t
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 /PRNewswire/ ... that widens the obstructed blood vessels. This report ... and future prospects of the market. The report ... market snapshot that provides overall information of various ... section also provides the overall information and data ...
(Date:9/2/2015)... 2, 2015 About implantable medical devices ... to replace, augment, or repair damaged tissues or ... of applications including cosmetic, spinal, cardiovascular, ophthalmic, and ... different materials such as polymers, metals, ceramics, and ... medical devices market to grow at a CAGR ...
(Date:9/2/2015)...  The report on breast cancer therapeutics: pipeline analysis ... on the basis of the molecules which are currently ... lining of milk ducts or lobules responsible for supplying ... that can spread to other cells present in the ... is referred as lobular carcinoma, while the other that ...
Breaking Medicine Technology:Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Implantable Medical Devices Market 2015-2019 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3
... Corporation (Nasdaq: SIAL ) will be presenting at ... 1:30 PM ET in New York, NY. Interested parties may ... http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to ... Sigma-Aldrich is a leading Life Science and High ...
... 23, 2011 ViewRay™, Inc., a privately held ... clearance for its radiotherapy treatment planning and delivery ... the company,s new radiation therapy system, which combines ... in the late stages of development, the integrated ...
Cached Medicine Technology:ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software 2
(Date:9/3/2015)... ... ... Local filmmakers and now co-hosts of the up and coming podcast Path11 ... had great success in launching their Path11 Podcast with 23 episodes released since April ... is the well known Spiritual Catalyst and Linda Howe, leader in the field of ...
(Date:9/3/2015)... ... 2015 , ... Leading post-acute electronic medical record (EMR) software ... the company’s executive leadership team as VP of Product and as VP of ... product and project management. He has been with HealthWyse since 2000 in the ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... and efficient customer and technical support services to promote LodonalTM in Nigeria. The ... trial evaluating the efficacy and safety of the product. , Managing Director, Fidson ...
(Date:9/2/2015)... , ... September 03, 2015 , ... The Aspen ... services - two retreats geared towards kick-starting and inspiring wellness in the Roaring Fork ... a part of developing a whole mind-body approach to fitness - we are much ...
(Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
Breaking Medicine News(10 mins):Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:Fidson Partners US Firms on New Product Marketing 2Health News:Fidson Partners US Firms on New Product Marketing 3Health News:Fidson Partners US Firms on New Product Marketing 4Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2
... women receiving the same breast cancer treatments as Hispanic ... lower survival rates, were more likely to be diagnosed// ... to a study. ,For the study, ... M. D. Anderson Cancer Center and colleagues examined 2,140 ...
... According to a recent analysis by Metropolitan Transportation Authority, ... excessive dieting are among the top// causes, after the ... US subway. ,Asim Nelson, a transit ... statistics, taken between October 2005 and October 2006, shows ...
... among states and union territories to enforce screening of all ... disorder// that could lead to disabilities. ,Chandigarh ... children would be done to check any adverse fallout later. ... ,While poor people would be provided the facility ...
... giant-Coco Cola and Nestle have come together to manufacture a ... tea, caffeine and plant micronutrients. This is expected to hit ... consumers shed excess weight. ,According the chief scientist ... calories burnt. The soft drink company claims that detailed studies ...
... proposal released by Gov. Arnold Schwarzenegger recently, workers in ... benefit - to their// health and wealth. Employees will ... exempted from tax. ,The proposal is an ... reachable to the approximate 6.5 million Californians who are ...
... make you diabetic, says a study that tracked hospitalisation rates ... ,Type-two diabetes has seen a two-fold increase - from ... While scientists scramble to find explanations for the rise, experts ... , ,However, the study by Lawrence Lessner and colleagues ...
Cached Medicine News:Health News:Living Near Toxic Waste May Bring On Diabetes 2
The Perfecta PDA components provide the design and material choice imperative in today's cost conscious medical climate....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Medicine Products: